TRPA1 antagonists for pain relief by Koivisto, Ari et al.
pharmaceuticals
Review
TRPA1 Antagonists for Pain Relief
Ari Koivisto 1, Niina Jalava 1, Raymond Bratty 2 and Antti Pertovaara 3,*
1 Research and Development, Orion Corporation Orion Pharma, POB 425 (Tengströminkatu 8), 20101 Turku,
Finland; ari-pekka.koivisto@orionpharma.com (A.K.); niina.jalava@orionpharma.com (N.J.)
2 Research and Development, Orion Corporation, Orion Pharma, POB 6792, Nottingham NG1 1AH, UK;
raymond.bratty@orionpharma.com
3 Department of Physiology, Faculty of Medicine, (Haartmaninkatu 8) POB 63, University of Helsinki,
00014 Helsinki, Finland
* Correspondence: antti.pertovaara@helsinki.fi; Tel.: +358-(0)294125280
Received: 1 October 2018; Accepted: 23 October 2018; Published: 1 November 2018


Abstract: Here, we review the literature assessing the role of transient receptor potential ankyrin 1
(TRPA1), a calcium-permeable non-selective cation channel, in various types of pain conditions. In
the nervous system, TRPA1 is expressed in a subpopulation of nociceptive primary sensory neurons,
astroglia, oligodendrocytes and Schwann cells. In peripheral terminals of nociceptive primary sensory
neurons, it is involved in the transduction of potentially harmful stimuli and in their central terminals
it is involved in amplification of nociceptive transmission. TRPA1 is a final common pathway for a
large number of chemically diverse pronociceptive agonists generated in various pathophysiological
pain conditions. Thereby, pain therapy using TRPA1 antagonists can be expected to be a superior
approach when compared with many other drugs targeting single nociceptive signaling pathways. In
experimental animal studies, pharmacological or genetic blocking of TRPA1 has effectively attenuated
mechanical and cold pain hypersensitivity in various experimental models of pathophysiological pain,
with only minor side effects, if any. TRPA1 antagonists acting peripherally are likely to be optimal for
attenuating primary hyperalgesia (such as inflammation-induced sensitization of peripheral nerve
terminals), while centrally acting TRPA1 antagonists are expected to be optimal for attenuating pain
conditions in which central amplification of transmission plays a role (such as secondary hyperalgesia
and tactile allodynia caused by various types of peripheral injuries). In an experimental model of
peripheral diabetic neuropathy, prolonged blocking of TRPA1 has delayed the loss of nociceptive
nerve endings and their function, thereby promising to provide a disease-modifying treatment.
Keywords: inflammatory pain; neuropathic pain; nociceptive primary afferent nerve fiber; peripheral
diabetic neuropathy; spinal cord; transient receptor potential ankyrin 1
1. Introduction to TRP Channels
Terminals of nociceptive primary afferent nerve fibers express various types of ion channel
receptors that transduce noxious environmental stimuli into electric signals. Thereby, ion channel
receptors expressed on nociceptive nerve fiber terminals help to detect harmful stimuli in the
environment. Additionally, ion channel receptors expressed on central terminals of nociceptive
nerve fibers may amplify transmission of nociceptive signals to central pain-relay neurons. In
acute conditions, noxious stimuli detected by ion channel receptors on peripheral terminals induce
nociceptive signals that may evoke pain sensations and protective responses, such as axon and flexion
reflexes, that help to avoid tissue injury. In pathophysiological conditions, ion channel receptors
expressed on nociceptors may contribute to chronic pain and prolonged suffering.
Among ion channel receptors expressed on nociceptors are those belonging to the transient
receptor potential (TRP) family that transduce and thereby detect various aspects of potentially
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harmful stimuli. The best-known TRP channel is transient receptor potential vanilloid 1 (TRPV1) that
has unique sensitivity to capsaicin but it is also activated by noxious heat. Since there are several recent
reviews on the role of TRP channels in general or TRPV1 channels in particular in pain treatment
(e.g., [1–4]), this brief review focuses only on one member of the TRP family that according to a number
of studies is implicated in pain, transient receptor potential ankyrin 1 (TRPA1) as a target for pain relief.
2. TRPA1 in Transduction of Noxious Stimulation
TRPA1 is a calcium-permeable nonselective cation channel [5,6]. Biophysical and structural
properties of the TRPA1 channel are outside the scope of this article and have been thoroughly
reviewed elsewhere (e.g., [7–11]). In the nervous system, TRPA1 is expressed on a subpopulation of
TRPV1-expressing nociceptive primary afferent neurons [5], astrocytes [12], oligodendrocytes [13], and
on peripheral analogs of oligodendrocytes, Schwann cells [14]. In addition, among non-neuronal cells
expressing TRPA1 are epidermal keratinocytes, endothelium, and vascular smooth muscle [15].
Originally, TRPA1 was considered to detect noxious cold and thereby cold pain [5]. However, later
studies suggested that TRPA1 is involved in detecting cold hypersensitivity rather than physiological
cold pain [16]. Instead, there is abundant evidence indicating that TRPA1 is activated by various
types of irritant chemicals that include endogenous compounds produced by tissue injury. Among
the numerous chemicals activating TRPA1 are some spices (e.g., cinnamon, mustard oil, and
wasabi), formalin, reactive oxygen species (ROS), reactive nitrogen species, reactive carbonyl species,
cannabinoids, volatile anesthetics, etc. [7]. Thereby, TRPA1 channels expressed on nociceptors are
considered to be important as chemosensors of nociception.
Previously, mammalian TRPA1 was not considered to be a detector of noxious heat, unlike TRPA1
in Drosophila or rattle snakes [17]. However, recently it was reported that after redox modification and
exposure to some ligands human TRPA1 could be activated by heat [18]. Moreover, another recent
study showed that the detection of acute noxious heat stimuli in mice depends on three functionally
redundant TRP channels that include TRPA1 as well as TRPM3 and TRPV1 [19]. This finding may
explain why pharmacological or genetic blocking of the TRPA1 channel alone has not induced changes
in heat nociception in most of the earlier mammalian studies.
Responses of nociceptive primary afferent nerve fibers to noxious mechanical stimulation have
been attenuated by pharmacological or genetic blocking of the TRPA1 indicating that peripheral TRPA1
channels contribute to mechanical nociception [20,21]. Sensory neuron-specific deletion of TRPA1
produced attenuation of the limb withdrawal response evoked by mechanical stimulation [22]. While
this finding is in line with the hypothesis that TRPA1 expressed on sensory nerve fibers exerts a role
in transduction of mechanical pain, it leaves open the possibility that the sensory neuronal TRPA1
interacts with other transducer molecules on the neuronal membrane to evoke a mechanically-induced
sensory signal. Moreover, it should be noted that keratinocytes that are known to have a role in
nociception [23] and that also express TRPA1 [21,24] may also contribute to mechanical nociception.
Central mechanisms have been traditionally considered to be important in mechanical
hypersensitivity, unlike in heat hypersensitivity [25]. Thereby, when considering the potential
contribution of TRPA1 to mechanical hypersensitivity that may to a large extent be dependent on
central mechanisms, one needs to keep in mind the TRPA1-mediated amplification of transmission in
the spinal dorsal horn [26]. However, there is accumulating evidence indicating that also peripheral
mechanisms, including those involving TRPA1, may also contribute to mechanical hypersensitivity. In
line with this, mechanically evoked responses were facilitated by inflammation only in a population of
primary afferent nerve fibers expressing TRPA1 [27], and mechanical sensitization of nociceptors was
attenuated by pharmacological blocking of TRPA1 [28]. Immune cell-to-sensory neuron signaling was
recently shown to be among peripheral TRPA1-mediated mechanisms of nociceptor sensitization [29].
This included activation of the type 2 angiotensin II receptor on peripheral macrophages which triggers
production of reactive oxygen/nitrogen species leading to TRPA1-mediated nociceptor sensitization.
One more peripheral TRPA1-mediated mechanism contributing to mechanical hypersensitivity
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following nerve injury involves Schwann cell TRPA1. This has been proposed to orchestrate
neuroinflammation and oxidative stress that promote nociception [14].
3. TRPA1 in Secondary (Central) Hyperalgesia
After skin injury, the intact area surrounding the injury may be sensitized to innocuous as well as
noxious mechanical stimuli, leading to tactile allodynia and mechanical hyperalgesia, respectively [25].
The sensitization of intact skin surrounding the injury area has been called secondary hyperalgesia,
and it is typically observed with mechanical rather than thermal stimuli and central mechanisms
are involved [25]. In experimental animals, mechanical hyperalgesia in the intact skin area adjacent
to injury was reversed following intrathecal administration of a TRPA1 antagonist indicating that
spinal TRPA1 expressed on central terminals of primary afferent nerve fibers contributes to secondary
hyperalgesia [30,31]. Moreover, cutaneous blood flow response adjacent to the skin injury was reduced
following intrathecal administration of TRPA1, suggesting that spinal TRPA1 is involved in the dorsal
root reflex that through antidromic activation of nociceptive primary afferent nerve fibers contributes
to cutaneous neurogenic inflammation [32]. In line with these experimental animal results, a study
in humans showed that a gain-of-function mutation in TRPA1 increases secondary hyperalgesia and
neurogenic inflammation adjacent to an injury site [33].
A plausible mechanism explaining the contribution of spinal TRPA1 to central hyperalgesia is that
injury activity induces ROS in the spinal cord dorsal horn [34]. At least partly, ROS is released from
spinal cord microglia [35]. ROS is an established endogenous agonist of TRPA1 [36] that, on central
endings of nociceptive primary afferent nerve fibers, amplifies glutamate-mediated transmission to
spinal pain-relay neurons [26]. Additionally, injuries have been shown to induce spinal generation of
various other endogenous TRPA1 agonists, such as hepoxilin A3 or 5,6-EET [37]. However, among
cells expressing TRPA1 is also the astrocyte [12]. Injury-induced activation of spinal astrocytes has
been shown to contribute to pain hypersensitivity due to coupling to adjacent astrocytes or neurons,
which may promote the spread of excitation and thereby facilitate pain [38]. In line with this possibility,
gliogenic long-term potentiation in the spinal cord has been reported to exert a role in wide-spread
pain hypersensitivity following injury discharge [39].
4. TRPA1 in Sleep Deprivation-Induced Pain Hypersensitivity
Loss of sleep may intensify pain in the clinic and cause pain hypersensitivity in experimental
conditions [40]. Vice versa, pain may cause sleep disturbances. Spinal administration of TRPA1
antagonists in the rat has reversed pain hypersensitivity induced by sleep deprivation indicating
that spinal TRPA1 contributes to sleep deprivation-induced pain hypersensitivity [31]. This result
supports the hypothesis that sleep deprivation induces spinal generation of ROS through descending
pathways. This is potentially due to an effect on spinal astrocytes. In agreement with this, some of
the descending pathways have been shown to activate an NMDA-nitric oxide cascade [41] that has
been associated with activation of astrocytes in the spinal cord dorsal horn [42]. In activated spinal
astrocytes, D-amino acid oxidase (DAAO) generates hydrogen peroxide, which, through its effect on
TRPA1 on the central endings of nociceptive primary afferent nerve fibers, may amplify transmission
of pain-related signals from primary afferent nerve fibers to central neurons of the pain pathways.
This proposal is in line with the observations that the enhancement of pain-related behavior following
sleep loss was attenuated not only by a spinally administered TRPA1 antagonist but also by spinal
administration of carbenoxolone, an inhibitor of astrocytes [43], and by spinal administration of DAAO
inhibitors [44]. Collectively, these results indicate that spinal TRPA1 is a final common pathway for a
pain-promoting cascade induced by sleep loss. This proposal, however, does not exclude a parallel
contribution of other mechanisms promoting pain behavior. Based on experimental animal studies, it
may be hypothesized that TRPA1 antagonists could have a dual beneficial effect in some clinical pain
conditions that are associated with sleep disturbances. First, blocking TRPA1 may attenuate pain that
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promotes sleep loss. Second, TRPA1 block is expected to inhibit the pronociceptive circuitry driven by
sleep loss.
5. Peripheral (Painful) Diabetic Neuropathy
Peripheral (painful) diabetic neuropathy (PDN) is a common consequence of diabetes mellitus.
PDN may produce symptoms that vary from paraesthesiae and sustained pain to sensory deficits.
Small fiber functions (such as detection of pain and warmth) are affected early, and large fiber-mediated
functions (such as detection of vibrotactile stimuli) are affected later [45]. PDN is known to have
multiple mechanisms. There is accumulating evidence indicating that one of the earliest mechanisms
contributing to PDN is that involving TRPA1 [46]. In line with this, diabetes mellitus produces
endogenous substances, such as methylglyoxal and 4-hydroxy-nonenal [47,48] that are TRPA1
agonists [36].
Endoplasmic reticulum (ER) stress is present in diabetic peripheral neuropathy [49]. Experimental
induction of ER stress with tunicamycin was shown to drive neuropathic pain-like behavior without
inducing hyperglycemia [50]. Interestingly, pharmacological block of TRPA1 was able to reverse
tunicamycin-induced mechanical hypersensitivity [51]. ER stress is, therefore, a plausible candidate
mechanism for initiation and perhaps also for maintenance of neuropathic pain in early phase of
painful diabetic neuropathy. In the long term, release of diabetes-generated compounds may cause
a sustained influx of calcium ions through TRPA1 channels in nerve terminals [48]. This is expected
to result in axoplasmic calcium dysregulation and excitotoxicity [52]. Thereby, the sustained TRPA1
channel-mediated influx of calcium provides a possible early mechanism for dysfunction and loss of
small fiber endings. In agreement with this hypothesis, treatment with a TRPA1 antagonist delayed
the loss of substance P-like immunoreactivity-expressing small fiber endings and their nociceptive
function in diabetic animals [48]. In another experimental animal study, an increased concentration of
methylglyoxal caused by a glyoxylase inhibitor led to a pain phenotype in wild-type but not TRPA1
knockout animals. This finding is in line with the proposal that a substance produced in diabetes,
methylglyoxal, contributes to the TRPA1-mediated development of PDN symptoms [53]. These
experimental findings are in agreement with clinical observations demonstrating that methylglyoxal
is increased both in type 1 and type 2 diabetes [54] and that an increased level of methylglyoxal is
associated with the development of PDN symptoms [55,56]. In addition to TRPA1, Nav1.8 is among ion
channels that may contribute to the methylglyoxal-induced pain behavior in diabetic animals [55,57].
While TRPA1 expressed on distal nociceptive nerve endings exerts an important role in the
diabetes-induced structural and functional changes of small diameter nerve fibers, amplification of
nociceptive signals by spinal TRPA1 is likely to contribute to the induction and preservation of pain
facilitation in diabetic animals. This is suggested by the finding that while a systemically administered
TRPA1 antagonist effectively attenuated the maintenance of pain facilitation in diabetic animals [58], a
considerably lower dose of a TRPA1 antagonist was needed to attenuate diabetic pain hypersensitivity
following intrathecal than systemic or intraplantar application [30]. In line with this, intraplantar
injection of methylglyoxal recapitulated pain behavior observed in diabetic neuropathy and was
associated with activation of nociceptive spinal dorsal horn neurons [59].
Together, the above findings imply that while a TRPA1 antagonist, the effect of which is restricted
to the periphery, delays the development of experimental diabetes-induced early anatomical and
functional changes in TRPA1-expressing peripheral nociceptors, a peripherally restricted block of
TRPA1 is expected to have a considerably weaker effect against diabetes-induced pain behavior than a
TRPA1 antagonist that spreads also to the central nervous system (particularly to the spinal cord) to
attenuate TRPA1-mediated amplification of nociceptive transmission in diabetes (Figure 1).
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Figure 1. A schematic figure showing potential sites of action for TRPA1 in peripheral diabetic 
neuropathy (PDN). In the left (peripheral tissue), a possible cascade generated in diabetes that drives 
TRPA1 on nociceptive nerve endings, leading first to excitation that is followed by a loss of TRPA1-
expressing nociceptive nerve fiber endings and their function. Note also that activation of TRPA1 on 
keratinocytes and/or Schwann cells might contribute to facilitation of pain behavior. In the right 
(spinal cord), a possible cascade that drives TRPA1 on central terminals of nociceptive primary 
afferent nerve fibers in diabetic animals, leading to enhanced transmission that, through central 
convergence of nociceptive signals to e.g., wide-dynamic range neurons, might contribute to 
allodynia. DRG: dorsal root ganglion. 
A recent mouse study showed that TRPA1 is involved in cold hypersensitivity while the 
diabetes-induced late mechanical hyposensitivity or the loss of PGP9.5-sensitive intraepidermal 
nerve fibers were not dependent on TRPA1, as revealed by a comparison of diabetic wild-type and 
TRPA1 knockout animals [60]. Pan-neuronal marker PGP9.5 labels various types of sensory nerve 
fibers, including those that do not express TRPA1 and that are involved in signaling mechanically 
evoked messages. Therefore, this finding supports the proposal that TRPA1-independent metabolic 
mechanisms are involved in causing mechanical hyposensitivity and destruction of 
mechanoreceptive nerve fibers in prolonged diabetes. In the early phase of diabetes, in contrast, 
endogenous TRPA1 agonists may have a key role in the induction of the first symptoms and 
degenerative signs of PDN through action on a subpopulation of TRPA1-expressing nociceptive 
nerve fibers. Consequently, blocking the TRPA1 channel promises to be a mechanism-based 
treatment that can delay the development of PDN. With prolongation of diabetes, metabolic 
mechanisms are expected to exert a major role in PDN leading to a loss of various types of nerve 
fibers and mechanical hyposensitivity that are independent of TRPA1, as demonstrated in a recent 
mouse study [60]. 
Other Aspects Related to Experimental Models of PDN 
The streptozotocin (STZ)-induced rodent model has been commonly used in diabetes studies. It 
should be noted that STZ itself has been shown to activate TRPA1, which should be taken into 
consideration in the interpretations particularly when dealing with acute effects of STZ [61]. 
However, since single acute injection of STZ is enough to produce diabetes that lasts for months and 
STZ is eliminated from the circulation within a couple of hours [62], it does not seem likely that 
TRPA1-mediated effects that take place several weeks after the induction of diabetes could be 
explained by direct actions of STZ on TRPA1.  
Local injection of STZ to brain ventricles is used to model cognitive dysfunction, which is 
increasingly recognized as type 1 and 2 diabetes-related symptom [63]. Interestingly, STZ injection 
was shown to cause selective injury to myelin and axons but not systemic hyperglycemia [64]. It is 
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neuropathy (PDN). In the left (peripheral tissue), a possible cascade generated in diabetes that
drives TRPA1 on nociceptive nerve endings, leading first to excitation that is followed by a loss
of TRPA1-expressing nociceptive nerve fiber endings and their function. Note also that activation
of TRPA1 on keratinocytes and/or Schwann cells might contribute to facilitation of pain behavior.
In the right (spinal cord), a possible cascade that drives TRPA1 on central terminals of nociceptive
primary afferent nerve fibers in diabetic animals, leading to enhanced transmission that, through
central convergence of nociceptive signals to e.g., wide-dynamic range neurons, might contribute to
allodynia. DRG: dorsal root ganglion.
A recent mouse study showed that TRPA1 is involved in cold hypersensitivity while the
diabetes-induced late mechanical hyposensitivity or the loss of PGP9.5-sensitive intraepidermal
nerve fibers were not dependent on TRPA1, as revealed by a comparison of diabetic wild-type and
TRPA1 knockout animals [60]. Pan-neuronal marker PGP9.5 labels various types of sensory nerve
fibers, including those that do not express TRPA1 and that are involved in signaling mechanically
evoked messages. Therefore, this finding supports the proposal that TRPA1-independent metabolic
mechanisms are involved in causing mechanical hyposensitivity and destruction of mechanoreceptive
nerve fibers in prolonged diabetes. In the early phase of diabetes, in contrast, endogenous TRPA1
agonists may have a key role in the induction of the first symptoms and degenerative signs of PDN
through action on a subpopulation of TRPA1-expressing nociceptive nerve fibers. Consequently,
blocking the TRPA1 channel promises to be a mechanism-based treatment that can delay the
development of PDN. With prolongation of diabetes, metabolic mechanisms are expected to exert a
major role in PDN leading to a loss of various types of nerve fibers and mechanical hyposensitivity
that are independent of TRPA1, as demonstrated in a recent mouse study [60].
Other Aspects Related to Experimental Models of PDN
The streptozotocin (STZ)-i duced rodent model has been commonly used in diabetes studies.
It should be noted that STZ itself has been shown to activate TRPA1, which should be taken
into consideration in the interpretations particularly when dealing with acute effects of STZ [61].
However, since single acute injection of STZ is enough to produce diabetes that lasts for months
and STZ is eliminated from the circulation within a couple of hours [62], it does not seem likely that
TRPA1-mediated effects that take place several weeks after the induction of diabetes could be explained
by direct actions of STZ on TRPA1.
Local injection of STZ to brain ventricles is used to model cognitive dysfunction, which is
increasingly recognized as type 1 and 2 diabetes-related symptom [63]. Interestingly, STZ injection was
shown to cause selective injury to myelin and axons but not systemic hyperglycemia [64]. It is possible
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that local activation of TRPA1 by STZ in myelinating oligodendrocytes drives white matter injury
in such a model. In agreement with this, genetic deletion of TRPA1 from birth was shown to reduce
myelin basic protein and alter myelination profile in mouse brain [65]. In the central nervous system,
increased methylglyoxal following induction of experimental diabetes has been suggested to be a cause
for neurotoxic effects such as increased apoptosis of hippocampal neurons that has been associated
with cognitive dysfunction [66]. TRPA1 expressed on oligodendrocytes might play a role also in the
methylglyoxal-driven hippocampal damage observed in animals with experimental diabetes.
Muscle cramps are a common symptom in diabetes [67,68] and motoneuron injury is present in an
STZ-induced animal model of diabetes [69]. Recent human TRPA1 gain-of-function mutation carriers
suffered from a number of typical TRPA1 overactivation-related symptoms but cramp-fasciculation
syndrome was a novel symptom not previously associated with TRPA1 [70]. Interestingly, TRPA1 is
expressed also in human motoneurons [24]. This clinical genetic finding raises the question whether a
centrally acting TRPA1 antagonist might have potential to treat cramp-fasciculation symptoms.
6. Peripheral Traumatic Neuropathy
Peripheral nerve injuries are known to induce pain and hypersensitivity [45]. Pain hypersensitivity
induced by peripheral nerve injury has been attenuated by blocking TRPA1 [71,72]. Amplification of
the pain-related signal transmission by spinal TRPA1 contributes to neuropathic hypersensitivity. This
is indicated by the observation that a low intrathecal dose of a TRPA1 antagonist effectively reduced
hypersensitivity in animals with a spinal nerve ligation-induced neuropathy [31]. In animals with
spinal nerve ligation-induced neuropathy, TRPA1 mRNA was down-regulated in the ligated nerve and
up-regulated in the adjacent intact nerves [73], although TRPA1 mRNA results following peripheral
nerve injuries have been variable (see for references in [74]). Interestingly, it was earlier reported
that intact nerves adjacent to the injured nerve may contribute to neuropathic pain [75] providing a
potential explanation for the up-regulation of TRPA1 mRNA in intact nerves.
The amygdala, a key structure for primary emotions, is also involved in processing and control of
pain. Recently, it was reported that amygdaloid microinjections of antioxidants or selective TRPA1
antagonists attenuated mechanical hypersensitivity and pain affect in nerve-injured animals [76].
While immunocytochemical and molecular biological evidence for amygdaloid TRPA1 expression in
neuropathic animals is still missing, this pharmacological finding suggests that nerve injury induces
oxidative stress and potentially amygdaloid expression of TRPA1 in neuropathy. Furthermore, the
finding suggests that a systemically administered TRPA1 antagonist might attenuate processing of
nociception and pain affect in peripheral neuropathy at multiple levels of the neural system.
7. Chemotherapy-Induced Neuropathy
A common side-effect of drugs used for the chemotherapy of cancer is neuropathy that is
associated with severe cold and mechanical allodynia. In experimental animal studies, blocking
TRPA1 has effectively attenuated cold and mechanical allodynia induced by anti-cancer drugs,
such as paclitaxel or oxaliplatin, indicating that TRPA1 is involved in chemotherapy-induced
neuropathy [77,78]. Concerning potential clinical applications, a promising experimental animal
finding is that a brief prophylactic treatment with a TRPA1 antagonist before start of the chemotherapy
effectively prevented the development of the chemotherapy-induced neuropathy [79].
8. Osteoarthritis
Osteoarthritis is a common disorder that causes pain in joints. Osteoarthritis typically causes
destruction of articular cartilage, formation of new bone in the subchondral region, and formation of
new bone and cartilage at the joint margins. In experimental animal studies, monosodium iodoacetate
is commonly used to induce osteoarthritis. In animals with experimental osteoarthritis, blocking
pharmacologically TRPA1 attenuated mechanical hypersensitivity in nociceptive neurons of the spinal
dorsal horn [80], while TRPA1 block did not attenuate sustained pain as revealed by a conditioned
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place preference test [81]. These results indicate that TRPA1 has a more important role in mechanical
hypersensitivity than ongoing pain in osteoarthritic animals. Pharmacological or genetic TRPA1
block has attenuated not only hypersensitivity but also inflammation induced by osteoarthritis [82],
although not in all experimental conditions [83]. Recently, TRPA1 was shown to be functionally
expressed in primary human osteoarthritic chondrocytes that possibly explains some of the symptoms
of osteoarthritis and provides a potential drug treatment target [84].
9. Postoperative Pain
Surgical operations induce ongoing pain and hypersensitivity of the operated area.
Pharmacological block of TRPA1 has attenuated guarding behavior, an index of sustained pain,
and mechanical hyperalgesia in a rat model of postoperative pain induced by skin and muscle tissue
incision in the paw [85]. Local administration of TRPA1 antagonists into the operated area attenuated
guarding behavior and mechanical hyperalgesia, while administration of TRPA1 antagonists into
the contralateral control area had no effect on pain behavior. This finding indicates that the critical
site for the pain suppression induced by pharmacological block of TRPA1 is the peripheral injury
site. Moreover, spinal TRPA1 was involved in mechanical allodynia (i.e., hypersensitivity to low
intensity stimuli), since it was attenuated by spinal administration of TRPA1 antagonists [85]. This
result resembles that obtained in neuropathy models in which spinal TRPA1 was involved in mediating
mechanical allodynia-like symptoms [30,31]. It may be speculated that, in addition to peripherally
mediated hyperalgesia and ongoing pain, postoperative pain model can induce a central neuropathic
pain-like component that is expressed as spinal TRPA1-mediated mechanical allodynia. A mouse study
in which only skin was incised, however, reported that TRPA1 knockout does not attenuate mechanical
hypersensitivity [86]. Among possible explanations for this difference in results is a species difference
(rat versus mouse), a difference in the incised tissue (skin + deep tissue incision versus skin incision),
and other differences in the experimental procedures (e.g., pharmacological block versus knockout of
TRPA1). A recent rat study showed that both superficial and deep skin incisions increase release of
endogenous TRPA1 agonists (ROS and H2O2), but TRPA1 exerts a significant role in postoperative pain
behavior only following deep skin incision that is most prominently seen as attenuation of guarding of
the injured paw following topical administration of a TRPA1 antagonist [87].
10. Pain and Inflammation Induced by Bacterial Infection
The complete form of Freund´s adjuvant (CFA), a mixture that contains inactivated and dried
mycobacteria, causes acute pain, mechanical allodynia, swelling of tissue and chronic inflammation
when injected to the paw or knee. Several studies have demonstrated that the CFA-induced
inflammatory pain can be reduced by administration of selective TRPA1 antagonists or knockout
of TRPA1 [72,80,83,88–90]. This result indicates that bacteria can directly or indirectly drive
TRPA1-expressing sensory neurons and thereby cause pain and inflammation.
The question how microbes activate sensory neurons expressing TRPA1 has been addressed in
two elegant studies [91,92]. In one of them, it was shown that live bacterial load rather than tissue
swelling or immune activation correlates with hyperalgesia or pain in a mouse model of infection
induced by Staphylococcus aureus, a frequent cause of wound infections in humans [91]. The study
showed that bacteria can drive sensory neurons by a direct action. Moreover, activation of sensory
neurons was mediated by N-formyl peptides and alpha-hemolysin, substances that are released from
bacteria. The other investigation addressing the interaction of TRPA1 and microbes showed that
lipopolysaccharide (LPS) that is a typical cell wall constituent of Gram negative bacteria, can directly
drive TRPA1 and thereby induce pain and inflammation [92]. This observation is interesting since
it has been reported that toll-like receptor 4 (TLR-4) of the innate immunity system, that was earlier
regarded as the major LPS receptor, was not necessary for such an effect. Moreover, the TRPA1-related
neurogenic inflammation was enhanced by concurrent administration of LPS with another agonist
of TRPA1 such as 4-hydroxynonenal. This type of an additive effect may be highly pertinent in vivo,
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when multifarious inflammatory TRPA1 agonists are present and their levels are increased. However,
the LPS-induced hypothermia is not mediated by TRPA1, since knockout of TRPA1 did not influence
it [92].
Low grade metabolic endotoxemia (i.e., an increased blood plasma level of LPS) is prevalent in
metabolic syndrome and diabetes [93]. Accumulating evidence indicates that following an excessive
high-fat diet, gut microflora may act as a source of an increased systemic level of LPS [94]. An increase
in the systemic LPS level may enhance pain in diabetes and advance development of neuropathy, since
LPS is a TRPA1 agonist and it enhances the effect of other TRPA1 agonists such as 4-hydroxynonenal,
the concentration of which is increased in diabetes.
Low back pain is one of the most common chronic pain conditions and is often difficult to
treat. Pathophysiological mechanisms of low back pain are not well understood. One proposed
back pain mechanism is a chronic low grade bacterially induced inflammation. In a double-blind
randomized clinical trial, low back pain treatment for 100 days with antibiotics improved significantly
the primary outcomes, disease-specific disability and low back pain as well as a number of secondary
outcomes [95]. This result supports the hypothesis that chronic low grade bacterial inflammation
contributes to pathophysiology of low back pain. Moreover, patients with low back pain caused by
lumbar disc herniation were recently shown to have elevated plasma levels of methylglyoxal that is an
endogenous TRPA1 agonist [96]. Taking into account the potential role of bacterial interaction with
TRPA1 in generation of pain [91,92], an intriguing question is whether patients with low back pain
might benefit from a treatment with a selective TRPA1 antagonist that does not have the risks of a
long-term antibiotic treatment.
11. Migraine
Migraine patients have episodic headache attacks that are typically unilateral. The pain reaches
its maximum within a few hours and is associated with nausea and vomiting. Headache attacks in
migraine patients typically last from one or two hours up to three days. Migraine can be accompanied
by increased sensitivity to light, sound, movement, smell and it frequently causes nausea and vomiting.
About one third of migraine patients experience short-lived aura, such as colored flashes and transient
visual field defects, before onset of migraine attack.
So far, no clear endogenous cause of migraine headache has been established. However, a number
of exogenous triggers have been described that include cigarette smoke, exposure to glyceryl trinitrate,
a variety of odors and excessive use of some drugs. The wide variety of chemicals that are known to
trigger migraine present an arduous challenge to understand the molecular mechanisms inducing
migraine attack.
Changes in the cranial blood flow are tightly associated with migraine attacks implying that
neurovascular mechanisms play an important role in migraine. Nociceptive substance P- and calcium
gene-related peptide (CGRP)-expressing unmyelinated nerve fibers originating from trigeminal
ganglion innervate large cerebral vessels, pial vessels, large venous sinuses and dura mater in the
cranium. Activation of these afferent nerve fibers conveys nociceptive signals to the brain but the
release of CGRP induces also neurogenic inflammation in the peripheral tissue [97]. Capsaicin-sensitive
(i.e., TRPV1-expressing) nerve fibers have been shown to elicit meningeal vasodilation suggesting
that they may exert an important role in meningeal nociception [98]. Taking into account that TRPA1
is co-localized in a subpopulation of TRPV1-expressing neurons, this result supports the hypothesis
that meningeal TRPA1 may also contribute to migraine pain [99]. Additionally, the finding that a
wide diversity of chemical compounds are TRPA1 agonists is in line with the proposal that TRPA1 in
trigeminal neurons may be a common mechanism for a wide variety of migraine triggers. In line with
this, a number of migraine triggers have been identified as TRPA1 activators and a number of drugs
used for migraine treatment desensitize or inhibit TRPA1 [100]. Furthermore, TRPA1 activation causes
release of CGRP that is considered a pro-migraine peptide [100].
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Migraine attacks are more common in patients who have experienced infantile colic in their early
life than in those who do not have a history of infantile colic. This finding supports the hypothesis
that colic may be a form of migraine attack or that colic may prime for future migraine attacks [101].
Interestingly, TRPA1 is the last among the TRP channels in sensory neurons of rodents that is expressed
during development [102]. Based on this finding, it may be speculated that human TRPA1 expression
coincides temporally with the emergence of colic symptoms providing a possible link between TRPA1
activation and induction of colic symptoms. TRPA1 expression must be seen as a substrate and a
presumably food-borne or endogenous TRPA1 agonist as a trigger for colic, since not all children suffer
from colic.
Intranasal exposure to environmental and cigarette smoke irritant acrolein and some other TRPA1
agonists have been shown to induce neurogenic inflammation, increase meningeal blood flow and
CGRP release [103]. Moreover, these actions were prevented by selective antagonists of CGRP or
TRPA1. These findings indicate that exposure to various TRPA1 agonists in the environment can
induce migraine-like symptoms. Umbellulone is another irritant in the environment and an established
migraine trigger that has also been shown to drive human and rodent TRPA1 channels in vitro, evoke
neurogenic vasodilation and inflammation as well as migraine-associated hypersensitivity [104]. These
effects were prevented by HC-030031, a selective TRPA1 antagonist, and by sumatriptan, a commonly
used migraine drug [104].
Cortical spreading depression is a cellular depolarization wave that travels across the cerebral
cortex and that has a correlation with migraine aura [105]. It has been shown that cortical
spreading depression generates oxidative stress and thereby causes activation of TRPA1 in trigeminal
ganglia [106]. Local application of H2O2, an established TRPA1 agonist, to the meninges induced
electrical spiking activity in sensory neurons which is a sign of pronociception. The H2O2-induced
increase of excitability of trigeminal sensory neurons was mediated by action on TRPA1 as indicated
by reversal of the effect by a selective TRPA1 antagonist TCS-5861528 [106]. In agreement with this, a
recent study using brain slices demonstrated that the spread of cortical depression was facilitated by a
TRPA1 agonist and delayed by a block of TRPA1 [107].
In addition to compounds generated in oxidative stress, it may be predicted that there are multiple
mechanisms of migraine-like headache that involve TRPA1 activation in meningeal sensory neurons.
Among the candidates is nitroglycerin-induced migraine in which TRPA1 is directly driven by nitric
oxide [108]. A recent experimental animal study showed that while nitric oxide is involved in initiation
of periorbital allodynia and vasodilatation induced by exposure to glyceryl nitrate, a well-known
migraine trigger, only vasodilatation was shown to be maintained by a direct nitric oxide action,
whereas maintenance of allodynia proved to be a neuronal event mediated by TRPA1 activation and
ensuing oxidative stress [109]. Another member of gasotransmitter family that presumably has a role
in migraine, hydrogen sulfide, was shown to activate nociceptive trigeminal neurons partly due to
action on TRPA1 [110] potentially providing one more migraine mechanism involving TRPA1.
At least partly, headache in bacterial meningitis might depend on leakage of LPS and formyl
peptides from bacteria and cells since these substances have been shown to excite sensory neurons
expressing TRPA1 [91,92]. Mitochondrial encephalopathy that is associated with lactic acidosis and
stroke-like episodes (MELAS) might also involve TRPA1-mediated headache mechanisms [111], since
lactic acidosis-induced acidosis should activate human TRPA1 [112].
There is accumulating evidence indicating that genetic and epigenetic factors play a role in
explaining individual differences in migraine vulnerability and underlying pathophysiological
mechanisms. For example, TRPM8 was strongly linked to migraine in a human genome-wide
association study [113], while genome-wide studies have not revealed such a link between TRPA1 and
migraine. However, differential TRPA1 expression has been reported to be linked to individual heat
pain sensitivity in discordant twins and healthy volunteers. This was indicated by the finding that
increased methylation of the TRPA1 gene promoter correlated with the increased expression of TRPA1
in tissues and the increased heat pain sensitivity [114]. This observation indicates that epigenetic
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changes causing increased TRPA1 expression in sensory neurons may amplify heat nociception in
affected individuals, although under physiological conditions TRPA1 is not directly activated by
heat. In line with this, heat pain sensitivity is increased between migraine attacks in episodic and
chronic migraine patients [115]. It still remains to be studied whether migraine patients and/or infants
suffering from colic pain have a hypermethylated TRPA1 promoter and increased TRPA1 expression.
There is still a huge need for more effective treatment of migraine. Compelling evidence supports
the proposal that TRPA1 antagonists may provide a promising future alternative for the prevention
and acute treatment of migraine.
12. Visceral Pain
Pain of visceral origin, such as irritable bowel syndrome or chronic pancreatic pain, is still a
challenge to treat in the clinic. There is accumulating evidence from experimental animal studies
indicating that TRPA1 is expressed in the viscera and that it contributes to visceral pain (see for
reviews [116,117]). For example, experimental inflammatory hyperalgesia of the colon was associated
with up-regulation of TRPA1 and hyperalgesia was reduced by spinal administration of TRPA1
antisense oligodeoxynucleotide [118,119]. Experimental results on pancreatic pain indicate that TRPA1
mediates chronic pancreatic inflammation and pain. This is shown by the finding that a chemical
that induces strong pancreatitis when administered into the pancreatic duct of wild-type mice had a
markedly weaker effect in the pancreatic duct of TRPA1 knockout animals [120]. Importantly, early
administration of a TRPA1 or a TRPV1 antagonist attenuated the transition and development of
experimental pancreatic inflammation and pain from acute experimental to chronic, thereby providing
an effective disease-modifying therapy [121].
13. TRPA1 Agonists for Pain Treatment
There is preclinical evidence suggesting that TRPA1 agonism may contribute to the analgesic effect
induced by acetaminophen (paracetamol). This was shown by the finding that the reactive metabolite
of acetaminophen acts in vivo as a TRPA1 agonist and thereby attenuates pain behavior through
desensitization of sensory neurons expressing TRPA1 [122]. This result raises an intriguing question
whether TRPA1 agonism may be a general approach for developing new analgesic compounds.
It is easier to identify a novel TRPA1 agonist than a novel TRPA1 antagonist scaffold. While this
could be seen as an advantage for a drug development approach, several major challenges can be
foreseen from the drug discovery point of view when developing drugs, the effect of which is based
on TRPA1 agonism. First, the TRPA1 agonist-induced long-term sustained activation and possible
pore dilation of TRPA1 channel is expected to result in excessive inflow of calcium and consequently,
excitotoxicity [48]. Second, most of the identified TRPA1 agonists are reactive substances. This raises
questions about risks associated with reactive compounds and their metabolites that may lead to
idiosyncratic adverse drug reactions. Third, in several pathophysiological pain conditions, generation
of several chemically diverse endogenous TRPA1 agonists is increased. Before a synthetic agonist of
TRPA1 is used for pain treatment, the possibility that it enhances rather than reduces pain needs to be
excluded. Therefore, it might be argued that developing an antagonist or negative allosteric modulator
of TRPA1 could be a more straightforward and successful way to develop new drugs for the treatment
of pain conditions that involve contribution of TRPA1.
14. TRPA1 Antagonists
Among challenges in the development of TRPA1 antagonists is a notable species difference
due to which some TRPA1 antagonists may be inactive in rodent TRPA1 that effectively prevents
preclinical efficacy and safety studies [123]. On the other hand, the finding that the percentage of TRPA1
expressing human dorsal root ganglion neurons (80%) is much higher than that of mouse dorsal root
ganglion neurons (40%) [124] raises the possibility that preclinical rodent studies may underestimate
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the potential efficacy of TRPA1 antagonists in clinical pain treatment. Various other challenges in the
drug discovery process of TRPA1 antagonists have been briefly reviewed elsewhere [125].
Several pharmaceutical companies have actively been working on novel small molecule TRPA1
antagonists and optimizing existing scaffolds. Hydra Biosciences was the first company to disclose
xanthine derivatives as TRPA1 antagonists, of which HC-030031 is a representative compound [126].
HC-030031 proved to be efficacious in vivo at 100 and 300 mg/kg. Another xanthine derivative
Chembridge-5861528 was explored by Orion Pharma as a tool compound. It was shown to be
about 10-fold more potent than HC-030031 [58]. Abbott disclosed a highly potent oxime derivative
A-967079 (WO/2009/089082) that failed to show efficacy after oral administration in neuropathic
pain models [127]. This result, however, may be explained by a limited access of A-967079 to the
brain/spinal cord [9]. Amgen has disclosed a series of trichloro(sulfanyl)ethyl benzamides as potent
TRPA1 antagonists, that were shown to be active only in human but not in rat TRPA1 [123]. Glenmark
Pharmaceuticals has extensively characterized and expanded the chemical space identified by Hydra
Biosciences. The most advanced compound developed by Glenmark Pharmaceuticals is GRC17536.
For other compounds and their structures developed by various companies, see a recent review
elsewhere [125].
Concerning testing of TRPA1 antagonists in humans, Hydra Biosciences/Cubist Pharmaceuticals
have reported about a successful phase 1 study with their compound CB-625. However, the
development of CB-625 was discontinued by Cubist Pharmaceuticals due to its low solubility. Orion
Pharma conducted a phase 1 study with ODM-108, a highly potent TRPA1 antagonist with preference
for human over rat TRPA1 receptors. This study was terminated due to complex pharmacokinetics.
There were no safety concerns at the doses administered (adverse effects, vital signs, measures of
sedation; NCT02432664 @ clinicaltrials.gov). Glenmark Pharmaceuticals has performed a phase 2
study in patients suffering from PDN and asthma. Patients with PDN may be classified into several
subgroups based on their somatosensory phenotype [128]. In a Glenmark study, a peripherally
restricted TRPA1 antagonist proved to be effective particularly in “an irritable nociceptor subgroup” of
diabetic patients, in whom the symptoms are likely to be peripherally driven (WO/2016/042501). This
result leaves open the question whether a TRPA1 antagonist that spreads to the central nervous system
might be effective in a subgroup of patients in whom central mechanisms contribute to the symptoms,
such as presumably in those with tactile allodynia. It is to be expected that with the development of
novel TRPA1 antagonists the properties of which are optimal for clinical use, there will be more human
studies allowing more conclusive interpretations on their role in clinical pain treatment.
15. Conclusions
TRPA1 is a final common pathway for many pronociceptive agonists generated in various
pathophysiological pain conditions, and for this reason it is a promising pain treatment target. In
experimental animal studies, blocking TRPA1 has effectively attenuated pain behavior in many
pathophysiological pain conditions. Depending on whether the TRPA1-mediated pronociception
is due to enhanced transduction in the periphery, amplification of transmission centrally or both,
pain treatment with a TRPA1 antagonist requires a compound that acts peripherally and/or centrally.
Concerning PDN, treatment with a centrally acting TRPA1 antagonist alone is expected to treat
patients with irritable nociceptor phenotype as well as a patient subgroup that suffers from mechanical
hyperalgesia; i.e., 75% of PDN patients [129]. Prolonged blocking of TRPA1 has even had a
disease-modifying effect in PDN, as shown by a delayed loss of a nociceptive nerve endings and their
function in experimental diabetes. While the first phase 1 and 2 studies in humans have given some
promising results e.g., in a subpopulation of PDN patients, additional study populations and probably
also novel TRPA1 antagonists still need to be tested before making conclusive interpretation about the
potential role of TRPA1 antagonists in clinical pain treatment.
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